CN111812228A - Method for measuring metoprolol tartrate and tablet impurities by ultra-high performance liquid chromatography - Google Patents
Method for measuring metoprolol tartrate and tablet impurities by ultra-high performance liquid chromatography Download PDFInfo
- Publication number
- CN111812228A CN111812228A CN202010564963.XA CN202010564963A CN111812228A CN 111812228 A CN111812228 A CN 111812228A CN 202010564963 A CN202010564963 A CN 202010564963A CN 111812228 A CN111812228 A CN 111812228A
- Authority
- CN
- China
- Prior art keywords
- mobile phase
- metoprolol tartrate
- minutes
- solution
- impurities
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/34—Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N2030/022—Column chromatography characterised by the kind of separation mechanism
- G01N2030/027—Liquid chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
- G01N2030/065—Preparation using different phases to separate parts of sample
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention belongs to the field of analytical chemistry, and particularly relates to a method for measuring metoprolol tartrate and tablet impurities by ultra-high performance liquid chromatography, which adopts a Waters ultra-high performance liquid chromatograph, a chromatographic column with octadecylsilane chemically bonded silica as a filler, and a mobile phase comprising a mixed buffer solution and acetonitrile in a volume ratio of 97: 3 is a mobile phase A, and the volume ratio of the mixed buffer solution to the acetonitrile is 30: mobile phase B, 70, gradient elution. The method not only can completely separate and detect 11 known impurities loaded in each pharmacopoeia at the same time, but also can separate and detect other impurities of the metoprolol tartrate and the tablets, particularly impurities Q and maltol, can more simply, conveniently, efficiently and accurately ensure the controllable quality of the metoprolol tartrate and the tablets and finally determine the safety of the product.
Description
Technical Field
The invention belongs to the field of analytical chemistry, and particularly relates to a method for determining metoprolol tartrate and tablet impurities by using ultra-high performance liquid chromatography.
Background
Metoprolol Tartrate (Metoprolol Tartrate), the chemical name of which is (+/-) -1-isopropylamino-3- [4- (2-methoxyethyl) phenoxy ] -2-propanol L (+) -Tartrate, has the molecular formula of (C15H25NO3) 2. C4H6O6, the molecular weight of 684.82 and the CAS number of 56392-17-7, and the structural formula of the Metoprolol Tartrate is shown as a compound in the following formula (a).
Metoprolol tartrate is a selective beta-1 adrenoceptor blocker. On 18 th of 4 th of 1975, metoprolol tartrate tablets were marketed by Aslican, Sweden under the trade name Seloken at 50mg and 100 mg. Is mainly used for treating diseases such as hypertension, angina, myocardial infarction and the like. In the synthesis process of metoprolol tartrate, relevant process impurities or degradation impurities are generated, the impurities can affect the purity and quality of raw materials due to incomplete removal, and the relevant degradation impurities can affect the quality and stability of metoprolol tartrate tablets, 13 currently known processes and degradation impurities are needed, so that the 13 impurities need to be subjected to quality control in metoprolol tartrate bulk drugs and preparations, and therefore, the separation and determination of the metoprolol tartrate and tablet impurities have important meanings for the production and storage of the metoprolol tartrate raw materials and preparations, and the structural formulas of the 13 impurities are as follows:
at present, the analysis and detection method for related substances of metoprolol tartrate is loaded in Chinese pharmacopoeia, United states pharmacopoeia, European pharmacopoeia and British pharmacopoeia, and high performance liquid chromatography is adopted. Wherein, the Chinese pharmacopoeia adopts octadecylsilane chemically bonded silica gel as a filler, acetate buffer solution (taking 3.9g of ammonium acetate, adding 810ml of water for dissolution, adding 2.0ml of triethylamine, 10.0ml of glacial acetic acid and 3.0ml of phosphoric acid, shaking up) -acetonitrile 824: 146, performing isocratic elution for the mobile phase, wherein the flow rate is 2ml/min, the column temperature is 30 ℃, the detection wavelength is 280nm, the sample injection volume is 20 mu l, the detection time is 3 times of the retention time of a main peak, and the impurity detection is performed by adopting a self-contrast method with a correction factor; the European pharmacopoeia and the British pharmacopoeia are the same, octadecylsilane chemically bonded silica is used as a filling agent, 3.9g of ammonium acetate and 810ml of water are added for dissolution, 2.0ml of triethylamine, 3.0ml of phosphoric acid and 10.0ml of glacial acetic acid are added for dissolution, 146ml of acetonitrile is added for uniform mixing to be used as a mobile phase for isocratic elution, the flow rate is 1ml/min, the detection wavelength is 280nm, the sample injection volume is 20 mu l, the detection time is 3 times of the retention time of a main peak, and the self-contrast method with a correction factor is adopted for detecting impurities; the United states pharmacopoeia uses octyl silane bonded silica gel as filler (4.6 mm. times.150 mm; 5 μm), 1.3g/L sodium dodecyl sulfate (containing 0.1% (w/v) phosphoric acid): acetonitrile 600: performing isocratic elution with a mobile phase of 400, wherein the flow rate is 1ml/min, the column temperature is 30 ℃, the detection wavelength is 223nm, the sample injection volume is 10 mu l, and detecting impurities by adopting an external standard method; however, none of the above methods can simultaneously separate and detect the 13 impurities described above.
In addition, the analysis and detection method of related substances of the metoprolol tartrate tablet is loaded in the Chinese pharmacopoeia, the United states pharmacopoeia and the English pharmacopoeia, wherein the detection method of the Chinese pharmacopoeia is the same as that of the metoprolol tartrate, the detection method of the British pharmacopoeia is basically the same as that of the metoprolol tartrate, the American pharmacopoeia adopts octadecylsilane chemically bonded silica as a filling agent (4.6mm multiplied by 150 mm; 5 mu m), 3.9g of ammonium acetate and 810ml of water are added for dissolution, 2.0ml of triethylamine, 3.0ml of phosphoric acid and 10.0ml of glacial acetic acid (pH is adjusted to 3.7) are taken as a mobile phase A, and acetonitrile: mobile phase a 70: and 30, performing gradient elution on the mobile phase B, wherein the gradient elution method comprises the following steps: maintaining the mobile phase A at 90% and the mobile phase B at 10% for 0 min; from 0min to 15 min, mobile phase a decreased linearly to 80%, mobile phase B increased linearly to 20%; from 15 minutes to 30 minutes, mobile phase a decreased linearly to 40% and mobile phase B increased linearly to 60%; 30-40 minutes, the mobile phase A maintains 40%, and the mobile phase B maintains 60%; from 40 minutes to 40.1 minutes, mobile phase a increased linearly to 90%, mobile phase B decreased linearly to 10%; from 40.1 minutes to 45 minutes, mobile phase a was maintained at 90% and mobile phase B at 10%. The flow rate is 1ml/min, the detection wavelength is 275nm, the sample injection volume is 20 mu l, and the impurity detection is carried out by adopting an external standard method; however, none of the above three methods can simultaneously separate and detect the 13 impurities described above.
Disclosure of Invention
In view of the above, the present invention aims to provide a method for measuring metoprolol tartrate and tablet impurities by ultra-high performance liquid chromatography, which can achieve separation and content detection of the 13 impurities simultaneously by a metoprolol tartrate reference product external standard method with correction factors added, thereby greatly improving work efficiency and saving time cost.
In order to achieve the purpose, the technical scheme of the invention is as follows:
a method for measuring metoprolol tartrate and tablet impurities by using ultra-high performance liquid chromatography is disclosed, wherein a chromatographic column adopted in the analysis process of the ultra-high performance liquid chromatography uses octadecylsilane chemically bonded silica as a filling agent, and a mobile phase uses a mixed buffer solution and acetonitrile in a volume ratio of 97: 3 is a mobile phase A, and the volume ratio of the mixed buffer solution to the acetonitrile is 30: and 70, carrying out gradient elution on the mobile phase B, wherein the gradient elution method comprises the following steps:
0 to 3 minutes, with 100% mobile phase a and 0% mobile phase B; from 3 minutes to 12 minutes, mobile phase a decreased linearly to 85% and mobile phase B increased linearly to 15%; from 12 minutes to 15 minutes, the mobile phase A is maintained at 85 percent, and the mobile phase B is maintained at 15 percent; from 15 minutes to 25 minutes, mobile phase a decreased linearly to 50% and mobile phase B increased linearly to 50%; from 25 minutes to 30 minutes, mobile phase a decreased linearly to 0% and mobile phase B increased linearly to 100%; 30-35 minutes, the mobile phase A maintains 0%, and the mobile phase B maintains 100%; from 35 minutes to 37 minutes, mobile phase a increased linearly to 100%, mobile phase B decreased linearly to 0%; from 37 minutes to 40 minutes, mobile phase a remained 100% and mobile phase B remained 0%.
The method is suitable for separating and detecting the 13 impurities, can be used for independently detecting one impurity and can also be used for simultaneously separating and detecting the 13 impurities.
The ultra-high performance liquid chromatography is reversed phase liquid chromatography, the adopted chromatographic column takes octadecylsilane chemically bonded silica as a filling agent, the particle size of the octadecylsilane chemically bonded silica is 1.7 mu m, the length of the chromatographic column is 100mm, the inner diameter of the chromatographic column is 2.1mm, and Waters ACQUITY is preferred
BEH C18 chromatography column. When the chromatographic column is used for separation, the applicable column temperature range of the chromatographic column is 30-40 ℃, and the preferred column temperature is 35 ℃.
In the above method, the mixed buffer solution is a mixed aqueous solution of phosphate and glacial acetic acid, and has a pH of 5.3-5.7, preferably 5.5.
In the above method, the phosphate is one or more of potassium dihydrogen phosphate, sodium dihydrogen phosphate, ammonium dihydrogen phosphate, dipotassium hydrogen phosphate, disodium hydrogen phosphate and diammonium hydrogen phosphate, and is preferably sodium dihydrogen phosphate.
In the above method, the concentration of phosphate in the mixed buffer solution is 0.015 to 0.025mol/L, preferably 0.02 mol/L; the volume percentage concentration of the glacial acetic acid is 1.8-2.2%, and the preferred volume percentage concentration is 2%.
In the method for measuring metoprolol tartrate and tablet impurities by using the ultra-high performance liquid chromatography, when the mobile phase is eluted by using the ultra-high performance liquid chromatography, the flow rate of the mobile phase is 0.38-0.42ml/min, and preferably 0.4 ml/min.
In the above method, the amount of the sample is 1 to 5. mu.l, preferably 2. mu.l.
After elution, the detection is carried out by using a DAD detector, and an ultraviolet detector is also suitable, and the detection wavelength is 273-277nm, preferably 275 nm.
The method comprises the following specific steps: respectively preparing system applicable solution, reference solution, sensitivity test solution and raw material and tablet test solution, injecting samples, and calculating the content of each impurity in the test sample by a metoprolol tartrate reference sample external standard method adding correction factors.
The applicable liquid of the system is as follows: respectively taking about 12.5mg of the 13 impurity reference substances, precisely weighing, placing in a 25ml measuring flask, adding a proper amount of solvent to dissolve and fix the volume to scale, shaking up to obtain impurity stock solutions, respectively measuring 0.5-1.5ml of each impurity stock solution, placing in a 25ml measuring flask, diluting to scale with the solvent, shaking up to obtain the system applicable solution.
The solvent was 0.02mol/L sodium dihydrogen phosphate, 2% glacial acetic acid buffer (pH 5.5) and acetonitrile at a volume ratio of 85: 15.
The above control solutions were: precisely weighing about 10mg of metoprolol tartrate reference substance, placing the reference substance into a 10ml measuring flask, adding a solvent to dissolve and dilute the reference substance to a scale, shaking up, precisely weighing 1ml, placing the reference substance into a 100ml measuring flask, adding the solvent to dilute the reference substance to the scale, and shaking up to obtain the reference solution.
The sensitivity test solution comprises: precisely measuring 1.8ml of the control solution, placing the control solution into a 25ml measuring flask, diluting the control solution to a scale with a solvent, and shaking up to obtain the sensitivity test solution.
The test solution of the raw materials is as follows: taking a proper amount of the metoprolol tartrate sample, precisely weighing, dissolving with a solvent and diluting to prepare a sample solution containing the metoprolol tartrate with the concentration of 5 mg/ml.
The test solution of the tablet is as follows: taking 20 test samples of metoprolol tartrate tablets, precisely weighing, grinding into fine powder, weighing a proper amount of fine powder, precisely weighing, adding a proper amount of solvent, carrying out ultrasonic treatment for 30min, taking out, cooling to room temperature, diluting with the solvent to prepare a solution containing 5mg/ml of metoprolol tartrate, shaking uniformly, filtering, and taking a subsequent filtrate.
Drawings
FIG. 1 is a chromatogram of a liquid suitable for use in the system
FIG. 2 is a chromatogram of a control solution
FIG. 3 is a chromatogram of a sensitivity test solution
FIG. 4 is a chromatogram of a sample solution
FIG. 5 is a chromatogram of a tablet test solution
Detailed Description
The examples are provided for better illustration of the present invention, but the present invention is not limited to the examples. Therefore, those skilled in the art should make insubstantial modifications and adaptations to the embodiments of the present invention in light of the above teachings and remain within the scope of the invention.
Example 1
The apparatus and chromatographic conditions used were as follows:
(1) ultra-high performance liquid chromatograph: waters UPLC H-class
A detector: PDA (personal digital Assistant)
A chromatographic workstation: empower
(2) A chromatographic column: WatersACQUITY
BEH C18 chromatography column (1.7 μm, 2.1 mm. times.100 mm)
(3) Mobile phase a phase: the volume ratio of 0.02mol/L sodium dihydrogen phosphate, 2% glacial acetic acid mixed buffer solution (pH 5.5) and acetonitrile was 97: 3. mobile phase B phase: the volume ratio of 0.02mol/L sodium dihydrogen phosphate, 2% glacial acetic acid mixed buffer solution (pH 5.5) and acetonitrile was 30: 70.
(4) detection conditions
Eluting the mobile phase A and the mobile phase B according to the following gradient proportion;
flow rate of mobile phase: 0.4 ml/min;
temperature of the column: 35 deg.C
Detection wavelength: 275nm
Sample introduction amount: 2 μ l
Gradiometer: 0 to 3 minutes, with 100% mobile phase a and 0% mobile phase B; from 3 minutes to 12 minutes, mobile phase a decreased linearly to 85% and mobile phase B increased linearly to 15%; from 12 minutes to 15 minutes, the mobile phase A is maintained at 85 percent, and the mobile phase B is maintained at 15 percent; from 15 minutes to 25 minutes, mobile phase a decreased linearly to 50% and mobile phase B increased linearly to 50%; from 25 minutes to 30 minutes, mobile phase a decreased linearly to 0% and mobile phase B increased linearly to 100%; 30-35 minutes, the mobile phase A maintains 0%, and the mobile phase B maintains 100%; from 35 minutes to 37 minutes, mobile phase a increased linearly to 100%, mobile phase B decreased linearly to 0%; from 37 minutes to 40 minutes, mobile phase a remained 100% and mobile phase B remained 0%.
Preparation of test solution
Solvent: the volume ratio of 0.02mol/L sodium dihydrogen phosphate, 2% glacial acetic acid buffer (pH 5.5) and acetonitrile was 85: 15.
Respectively taking about 12.5mg of the 13 impurity reference substances, precisely weighing, placing in a 25ml measuring flask, adding a proper amount of solvent to dissolve and fix the volume to scale, shaking up to obtain impurity stock solutions, respectively measuring 0.5-1.5ml of each impurity stock solution, placing in a 25ml measuring flask, diluting to scale with the solvent, shaking up to obtain the system applicable solution.
Precisely weighing about 10mg of metoprolol tartrate reference substance, placing the reference substance into a 10ml measuring flask, adding a solvent to dissolve and dilute the reference substance to a scale, shaking up, precisely weighing 1ml, placing the reference substance into a 100ml measuring flask, adding the solvent to dilute the reference substance to the scale, and shaking up to obtain a reference solution.
Precisely measuring 1.8ml of the control solution, placing the control solution into a 25ml measuring flask, diluting the control solution to a scale with a solvent, and shaking up to obtain the sensitivity test solution.
Raw material test solution: taking a proper amount of the metoprolol tartrate sample, precisely weighing, dissolving with a solvent and diluting to prepare a sample solution containing the metoprolol tartrate with the concentration of 5 mg/ml.
Tablet test solution: taking 20 test samples of metoprolol tartrate tablets, precisely weighing, grinding into fine powder, weighing a proper amount of fine powder, precisely weighing, adding a proper amount of solvent, carrying out ultrasonic treatment for 30min, taking out, cooling to room temperature, diluting with the solvent to prepare a solution containing metoprolol tartrate with the concentration of 5mg/ml, shaking uniformly, filtering, and taking a subsequent filtrate.
Procedure for the preparation of the
Respectively adding solvent, system application solution, control solution, sensitivity test solution, raw material sample solution and tablet sample solution into liquid chromatograph, measuring according to the above chromatographic conditions, and recording chromatogram, the results are shown in FIGS. 1-5. And calculating the content of each impurity in the sample according to a metoprolol tartrate reference product external standard method added with a correction factor.
The calculation formula is as follows:
the impurity content (%) - (Ax/As) × (Cs/Cx) × f × 100%
In the formula: ax: peak area of impurities in test solution
As: peak area of control solution
Cs: concentration of control solution (mg/ml)
Cx: concentration of metoprolol tartrate in test solution (mg/ml)
f: correction factor for each impurity
Note: impurity O is diastereoisomer, and is calculated by the sum of two peak areas
Typical maps are shown in FIGS. 1-5.
Example 2
The apparatus and chromatographic conditions used were as follows:
(1) ultra-high performance liquid chromatograph: waters UPLC H-class
A detector: PDA (personal digital Assistant)
A chromatographic workstation: empower
(2) A chromatographic column: WatersACQUITY
BEH C18 chromatography column (1.7 μm, 2.1 mm. times.100 mm)
(3) Mobile phase a phase: the volume ratio of 0.015mol/L sodium dihydrogen phosphate, 1.8% glacial acetic acid mixed buffer solution (pH 5.3) and acetonitrile is 97: 3. mobile phase B phase: the volume ratio of 0.015mol/L sodium dihydrogen phosphate, 1.8% glacial acetic acid mixed buffer solution (pH 5.3) and acetonitrile is 30: 70.
(4) detection conditions
Eluting the mobile phase A and the mobile phase B according to the following gradient proportion;
flow rate of mobile phase: 0.38 ml/min;
temperature of the column: 30 deg.C
Detection wavelength: 273nm
Sample introduction amount: 1 μ l
Gradiometer: 0 to 3 minutes, with 100% mobile phase a and 0% mobile phase B; from 3 minutes to 12 minutes, mobile phase a decreased linearly to 85% and mobile phase B increased linearly to 15%; from 12 minutes to 15 minutes, the mobile phase A is maintained at 85 percent, and the mobile phase B is maintained at 15 percent; from 15 minutes to 25 minutes, mobile phase a decreased linearly to 50% and mobile phase B increased linearly to 50%; from 25 minutes to 30 minutes, mobile phase a decreased linearly to 0% and mobile phase B increased linearly to 100%; 30-35 minutes, the mobile phase A maintains 0%, and the mobile phase B maintains 100%; from 35 minutes to 37 minutes, mobile phase a increased linearly to 100%, mobile phase B decreased linearly to 0%; from 37 minutes to 40 minutes, mobile phase a remained 100% and mobile phase B remained 0%.
The test solution was prepared as in example 1
The procedure is as in example 1
The calculation formula is the same as that of example 1
Example 3
The apparatus and chromatographic conditions used were as follows:
(1) ultra-high performance liquid chromatograph: waters UPLC H-class
A detector: PDA (personal digital Assistant)
A chromatographic workstation: empower
(2) A chromatographic column: WatersACQUITY
BEH C18 chromatography column (1.7 μm, 2.1 mm. times.100 mm)
(3) Mobile phase a phase: the volume ratio of 0.025mol/L sodium dihydrogen phosphate, 2.2% glacial acetic acid mixed buffer solution (pH 5.7) and acetonitrile was 97: 3. mobile phase B phase: the volume ratio of 0.025mol/L sodium dihydrogen phosphate, 2.2% glacial acetic acid mixed buffer solution (pH 5.7) and acetonitrile was 30: 70.
(4) detection conditions
Eluting the mobile phase A and the mobile phase B according to the following gradient proportion;
flow rate of mobile phase: 0.42 ml/min;
temperature of the column: 40 deg.C
Detection wavelength: 277nm
Sample introduction amount: 5 μ l
Gradiometer: 0 to 3 minutes, with 100% mobile phase a and 0% mobile phase B; from 3 minutes to 12 minutes, mobile phase a decreased linearly to 85% and mobile phase B increased linearly to 15%; from 12 minutes to 15 minutes, the mobile phase A is maintained at 85 percent, and the mobile phase B is maintained at 15 percent; from 15 minutes to 25 minutes, mobile phase a decreased linearly to 50% and mobile phase B increased linearly to 50%; from 25 minutes to 30 minutes, mobile phase a decreased linearly to 0% and mobile phase B increased linearly to 100%; 30-35 minutes, the mobile phase A maintains 0%, and the mobile phase B maintains 100%; from 35 minutes to 37 minutes, mobile phase a increased linearly to 100%, mobile phase B decreased linearly to 0%; from 37 minutes to 40 minutes, mobile phase a remained 100% and mobile phase B remained 0%.
The test solution was prepared as in example 1
The procedure is as in example 1
The calculation formula is the same as that of example 1
Example 4
The invention is researched by using the pharmaceutic adjuvant and the blank solvent used in the tablet process, and the pharmaceutic adjuvant and the blank solvent are found to have no interference to the invention.
The detection limits, quantitative limits, linearity and correction factors of the metoprolol tartrate and each impurity are detected, and the results are shown in tables 1 and 2.
TABLE 1 detection limit, quantitation limit test results for metoprolol tartrate and each impurity
TABLE 2 linearity of metoprolol tartrate and each impurity, calibration factor test results
As can be seen from tables 1 and 2, the metoprolol tartrate complex of the invention has high detection sensitivity for each impurity, and each impurity has good linear relationship in a lower concentration range.
Preparing a test sample solution of raw materials, injecting samples and recording maps at 0, 2, 4, 6, 8, 10, 12, 18 and 24 hours after preparation, counting and calculating the content of metoprolol tartrate and each impurity in the test sample, and calculating the relative standard deviation RSD of the content of the impurities C, F, E, three unknown impurities and metoprolol tartrate in the test sample to obtain 1.75 percent, 1.91 percent, 2.94 percent, 3.88 percent, 2.78 percent, 1.98 percent and 0.25 percent, and counting the number of newly generated impurities to be 0. The results show that the test solution is stable within 24 h.
Preparing a test solution of a tablet, injecting samples and recording maps at 0, 2, 4, 6, 8, 10, 12, 18 and 24 hours after preparation, counting and calculating the content of metoprolol tartrate and each impurity in the test solution, and calculating the relative standard deviation RSD of the content of the impurities C, F, E, three unknown impurities and metoprolol tartrate in the test solution to obtain 1.47 percent, 5.87 percent, 5.04 percent, 4.80 percent, 3.10 percent, 4.75 percent and 0.09 percent, wherein the number of other impurities is not detected, and counting the number of newly generated impurities to be 0. The results show that the test solution is stable within 24 h.
Recovery tests were performed on each impurity in the raw material and the tablet, respectively, and the results are shown in table 3.
Table 313 impurities recovery test results in metoprolol tartrate and tablets
Remarking: maltol is only a degradation product of tablets
As can be seen from Table 3, the recovery test results of the present invention were good in the raw material and the tablet.
The repeatability and the intermediate precision of the raw materials and the tablets are respectively tested, and the results show that the repeatability and the intermediate precision of the raw materials and the tablets meet the requirements and are good.
And taking the applicable liquid of the system for sample injection and recording the chromatogram map, wherein the separation degree of the metoprolol tartrate and each impurity can meet the requirement.
And (4) sampling a sensitivity test solution, and recording a chromatogram, wherein the signal-to-noise ratio of the metoprolol tartrate peak can be more than 10.
And continuously injecting the reference solution for 6 times, and recording a chromatogram, wherein the RSD of the 6-needle peak area of the metoprolol tartrate peak is less than 5 percent, meets the requirement, and can be used for calculating the content of impurities in the test sample.
Taking the raw materials and the tablet test sample solution respectively, injecting and recording chromatograms, and calculating the content of 13 impurities in the test sample according to a metoprolol tartrate reference sample external standard method with correction factors, wherein the results are shown in Table 4.
TABLE 4 content measurement results of metoprolol tartrate and each impurity in tablets
As can be seen from the results in Table 4 above, the metoprolol tartrate test sample contains known impurities C, E and F, and three unknown impurities; the content of impurities in the metoprolol tartrate tablet sample is the same as that of the raw materials.
The invention can quickly, effectively and accurately monitor the metoprolol tartrate and impurities in the tablet; the metoprolol tartrate compound has good specificity, the metoprolol tartrate peak can be separated from adjacent impurities among the impurity peaks, and the theoretical plate number of the metoprolol tartrate peak is more than 5000; the metoprolol tartrate and 13 impurity detection limits of the invention are smaller in quantitative limit; the sensitivity of the invention is high; the invention has good repeatability, intermediate precision and high recovery rate; in the invention, the linear relation between the metoprolol tartrate and 13 impurities is good within a wider concentration range; the method quantitatively analyzes 13 impurities by a metoprolol tartrate reference product external standard method with correction factors, and improves the detection accuracy of related substances.
Claims (10)
1. The method for measuring the metoprolol tartrate and the tablet impurities thereof by using the ultra-high performance liquid chromatography is characterized in that the ultra-high performance liquid chromatography and a DAD detector or an ultraviolet detector are adopted, octadecylsilane chemically bonded silica is used as a filling agent for a chromatographic column, and the volume ratio of a mixed buffer solution to acetonitrile is 97: 3 is a mobile phase A, and the volume ratio of the mixed buffer solution to the acetonitrile is 30: 70 is a mobile phase B, the detection wavelength is 273-277nm, the column temperature is 30-40 ℃, the flow rate is 0.38-0.42ml/min, the sample injection amount is 1-5 mu l, and gradient elution is carried out;
the mixed buffer solution is a mixed aqueous solution of phosphate and glacial acetic acid, the pH value is 5.3-5.7, and the gradient elution method comprises the following steps: 0 to 3 minutes, with 100% mobile phase a and 0% mobile phase B; from 3 minutes to 12 minutes, mobile phase a decreased linearly to 85% and mobile phase B increased linearly to 15%; from 12 minutes to 15 minutes, the mobile phase A is maintained at 85 percent, and the mobile phase B is maintained at 15 percent; from 15 minutes to 25 minutes, mobile phase a decreased linearly to 50% and mobile phase B increased linearly to 50%; from 25 minutes to 30 minutes, mobile phase a decreased linearly to 0% and mobile phase B increased linearly to 100%; 30-35 minutes, the mobile phase A maintains 0%, and the mobile phase B maintains 100%; from 35 minutes to 37 minutes, mobile phase a increased linearly to 100%, mobile phase B decreased linearly to 0%; from 37 minutes to 40 minutes, the mobile phase A is maintained at 100 percent, and the mobile phase B is maintained at 0 percent;
the impurities are:
2. the method for detecting metoprolol tartrate and tablet impurities thereof by ultra-high performance liquid chromatography as claimed in claim 1, wherein the particle size of the filler of the chromatographic column is 1.7 μm, the column length of the chromatographic column is 100mm, and the inner diameter of the filler of the chromatographic column is 2.1 mm.
3. The method for detecting metoprolol tartrate and tablet impurities thereof by ultra-high performance liquid chromatography as claimed in any one of claims 1 to 2, wherein the chromatographic column is Waters ACQUITY
BEH C18 chromatography column.
4. The method for detecting metoprolol tartrate and tablet impurities thereof by ultra-high performance liquid chromatography as claimed in claim 2, wherein the pH of the mixed aqueous solution of phosphate and glacial acetic acid is 5.5.
5. The method for detecting metoprolol tartrate and tablet impurities thereof according to claim 4, wherein the phosphate is one or more of potassium dihydrogen phosphate, sodium dihydrogen phosphate, ammonium dihydrogen phosphate, dipotassium hydrogen phosphate, disodium hydrogen phosphate and diammonium hydrogen phosphate.
6. The method for detecting metoprolol tartrate and tablet impurities thereof according to claim 5, wherein the phosphate is sodium dihydrogen phosphate.
7. The method for detecting metoprolol tartrate and tablet impurities thereof by ultra-high performance liquid chromatography as claimed in claim 6, wherein the concentration of phosphate in the mixed aqueous solution of phosphate and glacial acetic acid is 0.015-0.025mol/L, and the volume percentage concentration of glacial acetic acid is 1.8% -2.2%.
8. The method for detecting metoprolol tartrate and tablet impurities thereof by ultra-high performance liquid chromatography as claimed in claim 7, wherein the concentration of phosphate in a mixed aqueous solution of phosphate and glacial acetic acid is 0.02mol/L, the volume percentage concentration of glacial acetic acid is 2.0%, and the method comprises the following steps:
step 1, preparation of a solvent: a mixed solution with the volume ratio of the mixed buffer solution to the acetonitrile being 85: 15;
step 2, preparing a system applicable liquid: respectively taking about 12.5mg of the 13 impurity reference substances, precisely weighing, placing in a 25ml measuring flask, adding a proper amount of solvent to dissolve and fix the volume to a scale, shaking up to serve as impurity stock solutions, respectively taking 0.5-1.5ml of each impurity stock solution, placing in a 25ml measuring flask, diluting to the scale with the solvent, shaking up to serve as system applicable solutions;
step 3, preparing a control solution: precisely weighing about 10mg of metoprolol tartrate reference substance, placing the reference substance into a 10ml measuring flask, adding a solvent to dissolve and dilute the reference substance to a scale, shaking up, precisely weighing 1ml, placing the reference substance into a 100ml measuring flask, adding the solvent to dilute the reference substance to the scale, and shaking up to obtain a reference solution;
step 4, preparing a sensitivity test solution: precisely measuring 1.8ml of the control solution, placing the control solution in a 25ml measuring flask, diluting the control solution to a scale with a solvent, and shaking up to obtain a sensitivity test solution;
step 5, preparing a raw material test solution: taking a proper amount of metoprolol tartrate sample, precisely weighing, dissolving with a solvent and diluting to prepare a sample solution containing metoprolol tartrate with the concentration of 5 mg/ml;
step 6, preparation of a tablet test solution: taking 20 test samples of metoprolol tartrate tablets, precisely weighing, grinding into fine powder, weighing a proper amount of fine powder, precisely weighing, adding a proper amount of solvent, carrying out ultrasonic treatment for 30min, taking out, cooling to room temperature, diluting with the solvent to prepare a solution containing metoprolol tartrate with the concentration of 5mg/ml, shaking uniformly, filtering, and taking a subsequent filtrate;
and 7, respectively measuring a solvent, sampling a system applicable solution, a reference solution, a sensitivity test solution and a raw material and tablet test sample solution, and calculating the content of each impurity in the test sample by a metoprolol tartrate reference sample external standard method with a correction factor.
9. The method for detecting metoprolol tartrate and tablet impurities thereof by ultra-high performance liquid chromatography according to claim 8, wherein the flow rate of the mobile phase is 0.4 ml/min.
10. The method for detecting metoprolol tartrate and tablet impurities thereof by ultra-high performance liquid chromatography as claimed in claim 9, wherein the detection wavelength is 275 nm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010564963.XA CN111812228B (en) | 2020-06-19 | 2020-06-19 | Method for measuring metoprolol tartrate and tablet impurities thereof by ultra-high performance liquid chromatography |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010564963.XA CN111812228B (en) | 2020-06-19 | 2020-06-19 | Method for measuring metoprolol tartrate and tablet impurities thereof by ultra-high performance liquid chromatography |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111812228A true CN111812228A (en) | 2020-10-23 |
| CN111812228B CN111812228B (en) | 2021-11-05 |
Family
ID=72845285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010564963.XA Active CN111812228B (en) | 2020-06-19 | 2020-06-19 | Method for measuring metoprolol tartrate and tablet impurities thereof by ultra-high performance liquid chromatography |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111812228B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114544785A (en) * | 2020-11-24 | 2022-05-27 | 远大生命科学(辽宁)有限公司 | Method for detecting flurbiprofen and impurities thereof |
| CN115219633A (en) * | 2022-08-24 | 2022-10-21 | 山东齐都药业有限公司 | Gas chromatography detection method for residual solvent in metoprolol succinate bulk drug |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE68902001D1 (en) * | 1988-04-22 | 1992-08-13 | Astra Pharma Prod | METHOD FOR PRODUCING S-METOPROLOL AND ITS INTERMEDIATE PRODUCTS. |
| WO2005046568A2 (en) * | 2003-11-14 | 2005-05-26 | Ipca Laboratories Limited | Process for manufacture of metoprolol and salts thereof |
| CN101762649A (en) * | 2008-10-09 | 2010-06-30 | 北京德众万全药物技术开发有限公司 | Method for determining related substances of metroprolol succinate by using HPLC |
| CN102716091A (en) * | 2012-06-27 | 2012-10-10 | 武汉武药科技有限公司 | Method for preparing metoprolol tartrate particles |
-
2020
- 2020-06-19 CN CN202010564963.XA patent/CN111812228B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE68902001D1 (en) * | 1988-04-22 | 1992-08-13 | Astra Pharma Prod | METHOD FOR PRODUCING S-METOPROLOL AND ITS INTERMEDIATE PRODUCTS. |
| WO2005046568A2 (en) * | 2003-11-14 | 2005-05-26 | Ipca Laboratories Limited | Process for manufacture of metoprolol and salts thereof |
| CN101762649A (en) * | 2008-10-09 | 2010-06-30 | 北京德众万全药物技术开发有限公司 | Method for determining related substances of metroprolol succinate by using HPLC |
| CN102716091A (en) * | 2012-06-27 | 2012-10-10 | 武汉武药科技有限公司 | Method for preparing metoprolol tartrate particles |
Non-Patent Citations (4)
| Title |
|---|
| RAJA KUMAR SESHADRI ET AL.: "Simultaneous Quantitative Determination of Metoprolol, Atorvastatin and Ramipril in Capsules by a Validated Stability-Indicating RP-UPLC Method", 《SCIENTIA PHARMACEUTICA》 * |
| SAINATH KALISETTY ET AL.: "Ultra Performance Liquid Chromatographic Method Development And Validation For The Quantification Of Impurities And Degradation Products In The Metoprolol Succinate Er Tablets", 《INTERNATIONAL JOURNAL OF PHARMACY AND BIOLOGICAL SCIENCES》 * |
| 李群鑫 等: "HPLC法测定琥珀酸美托洛尔的含量及有关物质", 《中国药事》 * |
| 苏平: "HPLC法测定酒石酸美托洛尔注射液的含量和有关物质", 《中国药师》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114544785A (en) * | 2020-11-24 | 2022-05-27 | 远大生命科学(辽宁)有限公司 | Method for detecting flurbiprofen and impurities thereof |
| CN115219633A (en) * | 2022-08-24 | 2022-10-21 | 山东齐都药业有限公司 | Gas chromatography detection method for residual solvent in metoprolol succinate bulk drug |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111812228B (en) | 2021-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111812228B (en) | Method for measuring metoprolol tartrate and tablet impurities thereof by ultra-high performance liquid chromatography | |
| CN111551654B (en) | Method for detecting cefixime polymer impurities | |
| CN110441421B (en) | Method for determining dissolution rate of entacapone tablets by high performance liquid chromatography | |
| CN111122736B (en) | Method for detecting enantiomer in intermediate of brivaracetam | |
| CN111983055A (en) | Method for separating and measuring rivaroxaban intermediate related substances by using HPLC (high performance liquid chromatography) | |
| CN114280191B (en) | Method for detecting related substances in double-cysteine and preparation thereof | |
| CN110988158A (en) | Method for detecting related substances of tirofiban hydrochloride injection | |
| CN113358790B (en) | Method for detecting related substances in nicergoline and preparation thereof | |
| CN114689737B (en) | Analysis method of S-o-chlorophenylglycine methyl tartrate related substances | |
| CN114324642B (en) | Method for determining dextromethorphan hydrobromide related substances | |
| CN112034066B (en) | Method for separating and measuring Ribociclib and impurities | |
| CN112881538B (en) | Method for detecting impurities and enantiomers in fudosteine and fudosteine tablets | |
| CN114660183A (en) | High performance liquid chromatography analysis method for separating and measuring L-alanine isopropyl ester hydrochloride enantiomer | |
| CN112362780A (en) | High performance liquid detection method of propranolol hydrochloride | |
| CN114280190B (en) | Kit for detecting related substances of double cysteines | |
| CN115078572B (en) | Method for determining folic acid impurity by ultra-high performance liquid chromatography | |
| CN113866329B (en) | Method for detecting isocyanate potential genotoxic impurities in glimepiride tablets | |
| CN116124926B (en) | Method for determining content of 2-mercaptopyridine in plasmid | |
| CN117288868B (en) | Detection method of N-acetyl-L-leucine related substances | |
| CN114235998B (en) | Method for measuring related substances in carteolol hydrochloride and eye drops thereof by ultra-performance liquid chromatography | |
| CN111122742B (en) | Method for detecting residual quantity of dimercaptopolyethylene glycol in sample to be detected | |
| CN115963217B (en) | Detection method of imidapril intermediate and impurity | |
| CN113189224A (en) | Method for detecting related substances in gentamicin C1a alkali freeze-dried powder | |
| CN117825552A (en) | Evaporation light scattering detection method for lysine hydrochloride and calcium hydrophosphate | |
| CN115436532A (en) | Detection method of sitaxel intermediate 5, 7-dichloro-1, 2,3, 4-tetrahydroisoquinoline |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Yang Qi Inventor after: Liu Yan Inventor after: Wang Jing Inventor after: Liu Caixia Inventor after: Wang Lili Inventor after: Liu Yanxin Inventor after: Yang Shuai Inventor after: Liu Yafang Inventor after: Guo Lulu Inventor before: Yang Qi Inventor before: Liu Yan Inventor before: Wang Jing Inventor before: Liu Caixia Inventor before: Wang Lili Inventor before: Liu Yanxin Inventor before: Yang Shuai Inventor before: Liu Yafang Inventor before: Guo Lulu |
|
| CB03 | Change of inventor or designer information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |